Hatch/Lieberman “BioShield II” Sets 180-Day Window For “Wild Card” Patents
Executive Summary
Manufacturers who enter into biodefense contracts must notify the government within 180 days which patent would be covered by a potential "wild card" extension under the final version of "BioShield II" legislation from Sens. Orrin Hatch (R-Utah), Joe Lieberman (D-Conn.) and Sam Brownback (R-Kan.)
You may also be interested in...
Capitol Hill News In Brief
FDA budget in limbo: The 109th congress failed to pass FY 2007 appropriations for FDA, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen in the Senate and House - Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wis.) - plan to scrap the current Republican-designed appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008. FDA said "a full-year continuing resolution presents difficult challenges" and added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...
Capitol Hill News In Brief
FDA budget in limbo: The 109th congress failed to pass FY 2007 appropriations for FDA, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen in the Senate and House - Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wis.) - plan to scrap the current Republican-designed appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008. FDA said "a full-year continuing resolution presents difficult challenges" and added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...
Priority Review Voucher Proposal To Be Considered By FDA
Potential "blockbuster" drugs could receive faster FDA review under a proposed system to encourage development of treatments for neglected diseases